Physician profile
Brian Kirsh
NPI 1871592493
$7,755.18
in general payments reported to CMS, 2019-2025
31 companies · $2,090 in 2025
The $2,090 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2021: $334 · 2022: $798 · 2023: $2,324 · 2024: $2,098 · 2025: $2,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,488 · Education: $23.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,488.43 |
| Education | $23.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,713.77 | 2019-2025 | |
| Celgene Corporation | $790.28 | 2021-2024 | Zeposia |
| Genzyme Corporation | $643.26 | 2022-2025 | |
| Janssen Biotech, INC. | $629.84 | 2023-2025 | Stelara, Tremfya |
| Pfizer INC. | $555.63 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $477.23 | 2022-2025 | Entyvio, Gattex |
| E.R. Squibb & Sons, L.L.C. | $388.93 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $359.91 | 2021-2025 | Xifaxan, Trulance |
| Ardelyx, INC. | $349.16 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $301.05 | 2022-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $210.14 | 2022-2024 | Tremfya, Stelara |
| Conmed Corporation | $150.68 | 2021 | |
| Lilly USA, LLC | $150.64 | 2024-2025 | Omvoh, Zepbound |
| Aimmune Therapeutics, INC. | $126.85 | 2025 | Zenpep |
| Echosens North America, INC. | $121.00 | 2023 | Fibroscan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $114.66 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $100.19 | 2022-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $86.95 | 2023-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $72.94 | 2025 | Iqirvo |
| Novo Nordisk INC | $56.36 | 2025 | Wegovy |
| Amgen INC. | $47.43 | 2023 | Amjevita, Avsola |
| Stryker Corporation | $42.41 | 2024 | Neptune |
| Vibrant Gastro, INC. | $38.70 | 2024 | Vibrant Starter Kit |
| Fresenius Kabi USA, LLC | $38.53 | 2023-2024 | Idacio |
| Ferring Pharmaceuticals INC. | $36.06 | 2022-2024 | Rebyota |
| Qol Medical, LLC | $34.20 | 2023 | Sucraid |
| Braintree Laboratories, INC. | $29.78 | 2021-2025 | Suflave, Sutab |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.62 | 2023 | Cyltezo |
| Celltrion USA INC. | $23.95 | 2024 | Zymfentra |
| Daiichi Sankyo INC. | $21.49 | 2023 | Injectafer |
| Evoke Pharma, INC. | $17.54 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Kirsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.